V

ViroGates A/S
CSE:VIRO

Watchlist Manager
ViroGates A/S
CSE:VIRO
Watchlist
Price: 15.4 DKK -6.67% Market Closed
Market Cap: 119.1m DKK
Have any thoughts about
ViroGates A/S?
Write Note

ViroGates A/S
Capital Expenditures

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

ViroGates A/S
Capital Expenditures Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Capital Expenditures CAGR 3Y CAGR 5Y CAGR 10Y
V
ViroGates A/S
CSE:VIRO
Capital Expenditures
-kr1k
CAGR 3-Years
N/A
CAGR 5-Years
65%
CAGR 10-Years
N/A
GN Store Nord A/S
CSE:GN
Capital Expenditures
-kr1.4B
CAGR 3-Years
2%
CAGR 5-Years
-7%
CAGR 10-Years
-7%
Ambu A/S
CSE:AMBU B
Capital Expenditures
-kr289m
CAGR 3-Years
21%
CAGR 5-Years
-2%
CAGR 10-Years
N/A
Demant A/S
CSE:DEMANT
Capital Expenditures
-kr632m
CAGR 3-Years
-10%
CAGR 5-Years
-6%
CAGR 10-Years
-3%
No Stocks Found

ViroGates A/S
Glance View

Market Cap
119.1m DKK
Industry
Health Care

ViroGates A/S develops and markets prognostic products for the healthcare sector. Its develops a product line suPARnostic, which measures the amount of amount of soluble urokinase Plasminogen Activator Receptor protein (suPAR) in human blood. The plasma level of suPAR reflects immune activation and is increased in such infectious diseases as HIV-1-infection, malaria, tuberculosis, Streptococcus pneumonia bacteraemia, sepsis, pneumococcal pneumonia and bacterial and viral CNS infection. Also, high suPAR levels are associated with increased inflammation, disease progression and risk of mortality. Thus, measuring suPAR levels serves as a marker to determine chances for survival upon hospital admission, as well as for monitoring for prevention of disease progression and earlier intervention time point. suPARnostic has two versions: Quantitative Point of Care Quick Triage test, which serves for patient triage in acute care, and Quantitative ELISA Assay that aims at clinical routine use.

VIRO Intrinsic Value
3.42 DKK
Overvaluation 78%
Intrinsic Value
Price
V

See Also

What is ViroGates A/S's Capital Expenditures?
Capital Expenditures
-1k DKK

Based on the financial report for Sep 30, 2024, ViroGates A/S's Capital Expenditures amounts to -1k DKK.

What is ViroGates A/S's Capital Expenditures growth rate?
Capital Expenditures CAGR 5Y
65%

Back to Top